LenioBio Won Prestigious Horizon 2020 SME/2 Grant (FOTO)

Dusseldorf (ots) -

LenioBio GmbH today announced that the company has been awarded a
grant of EUR2.37 million to accelerate the scale-up of its
proprietary protein expression platform ALiCE®.

Today's drug development process is cumbersome and expensive. On
average, the time from discovery of a new protein drug to market
introduction spans 12 - 14 years and exceeds EUR2B. In all four
phases of drug development - drug discovery, pre-clinical studies,
clinical trials and commercial production - there are inefficiencies
that together constitute the problem. The ALiCE® platform will
address these inefficiencies and thereby cutting the drug-to-market
timelines by several years. The impact of our platform technology has
been recognized by the Horizon 2020 EU funding body, which awarded
LenioBio the funds to accelerate the development and implementation
of these much-needed solutions.

Remberto Martis, Ph.D., CEO of LenioBio, explained: "Our solution
is the first eukaryotic cell-free platform, scalable according to
customer's need. Simplified, ALiCE® is the concentrated protein
machinery of the cell. Currently, we concentrate the protein
machinery of the cell in mL ALiCE solution and offer it as Expression
kits to our customer. The Horizon funding will speed up the platform
development to 100L scale to service the need of the market. Thus,
our solutions for the drug development process are fast, scalable and
very cost-effective."

Ricarda Finnern, Ph.D., Chief Scientific Officer at LenioBio
concluded: "With our ALiCE® platform we have expressed proteins not
expressible in an economical way in other platforms, as well as other
proteins that were so far not expressible at all. This allows for
viable protein drug candidates to be discovered faster, as well as
enabling attractive candidates to be moved into clinical trials
faster. With the Horizon funding, our R&D team can now accelerate the
scaling and yield increase of the ALiCE® platform to deliver large
scale quantities of proteins for therapeutic use. Furthermore, the
linear scaling of the cell-free ALiCE® platform to production
quantities takes only months, instead of years in the cases of the
cell-based platform. The overall effect of these advantages of ALiCE®
will be a reduction in the long timelines of protein drug
development."

About LenioBio:

LenioBio GmbH is a protein expression platform company committed
to the advancement of transformative technology for the discovery,
development, and large-scale production of proteins, unconstrained by
the limitations of the cell.

LenioBio was established as a legal entity in Germany in September
2016, with offices in Dusseldorf and R&D and production labs in
Aachen. For more information about LenioBio, please visit our website
at www.leniobio.com.

About Horizon 2020

Horizon 2020 EU funding supports Small and Medium-sized
Enterprises (SME) with breakthrough innovation projects and a
market-creating potential. The highly competitive fund is only
offered to SMEs, which fall under the European Innovation Council's
(EIC) SME definition. The fund is part of the Horizon 2020 work
program 2018-2020, funding high-potential innovations in the EU. The
fund offers Europe's brightest and boldest innovators the funding for
breakthrough ideas with the potential to create entirely new markets
or revolutionize existing ones.

Media & Partnering Contact:
Hákon Birgisson, Ph.D., MBA Head of Business Development
h.birgisson@leniobio.com
Tel: +49211 8909 40300

Original-Content von: LenioBio GmbH, übermittelt durch news aktuell